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controlled fashion over 30 days. The intervention group experi-
enced a signiﬁcant decrease in portal hypertension that was addi-
tive to the effects of propranolol. Moreover, liver tests increased
more often with placebo than simvastatin [5].
The correspondents generalize, without support, that non-
USA physicians have no trouble giving statins to patients with
liver disease. In the editorial, I cite an international HCV treat-
ment study where the majority of authors are not from the USA
[6]. Only 3% of the 403 patients were on statins; whereas, given
the customary age range for participants in HCV studies, one
would expect 30% or more of these latter study patients to need
a statin. These data would seem to indicate a bias by hepatolo-
gists worldwide not to give statins to patients who have at least
hepatitis C disease.
The problem the correspondents fail to apprehend with
RUCAM methodology is its extremely low positive predictive
value (PPV). With RUCAM, the probability of a statin being cor-
rectly identiﬁed as the ‘‘true’’ cause of idiopathic test abnor-
malities is less than 1% [4]. That is, if the RUCAM determines
the statin is the culprit, 99 out of a 100 times it is wrong.
Not the type of certainty one would want in a court of law,
for example. While this level of uncertainty may be sufﬁcient
to withdraw a drug from a patient, it is not compelling enough
to conclude scientiﬁcally that statins cause idiosyncratic
reactions. Thus, there remains legitimate doubt as to whether
statins are responsible for rare instances of idiosyncrasy. All
of the cases presented by Bjornsson et al. could easily be
counted as background noise [7]. Nevertheless, until we
become more scientiﬁc and settle the issue with proteomics
and microarray testing, we are stuck with clinical opinion;
the variations of RUCAM represent only attempts to score clin-
ical judgment with numbers.
The terminology for the subject is critical otherwise the reader
will confuse what the message of statin mythology has been all
about. The letter writers use the term ‘‘hepatotoxicity’’ both as
a general term, and for predictable dose-dependent reactions. I
believe universal practice is to now use ‘‘DILI’’ or ‘‘drug-induced
liver injury’’ as a general term, and restrict hepatotoxicity to
the predictable, dose-dependent setting [8].
The remaining concerns of the correspondents have become
moot since the revisions of 28 February 2012 by the FDA.
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Letters to the EditorWhich is the real efﬁcacy of pegylated interferon alpha 2a or 2b
plus ribavirin in HCV infected patients with advanced ﬁbrosis?
To the Editor:
We have read with great interest the article of Prati et al. [1]. The
authors concluded that patients infected with HCV genotypes
1–4 that received PegIFNa-2A plus ribavirin with advanced ﬁbro-
sis (staging P3 according to Ishak classiﬁcation) had an end
treatment response (ETR) and sustained virological response
(SVR) rates that were not inﬂuenced by ﬁbrosis stage. In contrast,
PegIFNa-2B plus ribavirin was less effective than PegIFNa-2A and
led to a lower rate of both ETR and SVR in patients with staging
P3. We are concerned about part of the content of the paper.
The article analyzed a heterogeneous population of patients
infected with HCV that included ‘‘difﬁcult to treat patients’’
infected with genotypes 1–4 and ‘‘easy to treat patients’’ infected
with genotypes 2 and 3. Those infected with HCV genotypes 1-4
were analyzed together and stratiﬁed according to the Ishak clas-
siﬁcation staging score. However, several questions remain unan-
swered: What was the distribution of patients with genotype 4 in
the different staging groups? What was the percentage of Egyp-
tian patients in the genotype 4 group included in the study? In
Northern Italy, HCV genotype 4 was reported in about 2% of all
patients infected with HCV [2]. In addition, different studies have
reported that patients infected with genotype 4 presented a bet-
ter SVR compared to those infected with genotype 1, particularly
in patients that achieved a rapid virological response (RVR) [3,4].
Furthermore, Egyptian patients infected with genotype 4 with
advanced ﬁbrosis had a better SVR compared to European and
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African patients with genotype 4 that presented with a similar
stage of liver ﬁbrosis [5]. Therefore, we believe that the inclusion
of patients with genotype 4 could have inﬂuenced the SVR
achieved in the genotype 1–4 group of patients with stagingP3.
According to the Ishak classiﬁcation staging score, the stage 3
classiﬁcation is deﬁned as a ﬁbrous expansion over most of the
portal area with occasional ﬁbrous bridging from portal to portal
regions. In contrast, central-to-portal bridging ﬁbrosis, classiﬁed
as stage 4 in the Ishak score, is an important component of severe
chronic active hepatitis [6]. It is an important factor for rapid pro-
gression to cirrhosis, because contraction of collagen-rich bridges
may produce rapid, severe distortion of the normal hepatic
microstructure. In our opinion, stage 3 should not be considered
as a surrogate of advanced liver ﬁbrosis. The inclusion of stage 3
patients in a group with so called ‘‘advanced ﬁbrosis’’ might have
caused an underestimation of the impact of liver ﬁbrosis in
patients treated with PegIFNa-2A that achieved SVR.
We have studied 388 patients infected with genotype 1a/1b in
different stages, according to the Ishak classiﬁcation. Part of that
data was derived from our previous study [7]. We stratiﬁed the
patients according to S0–S3 and S4–S6 groups. We deﬁned
advanced ﬁbrosis as stages S4–S6. The patients were treated with
PegIFNa-2A at 180 lg/week plus ribavirin or with PegIFNa-2B at
1.5 lg/kg/week plus ribavirin. The two treatment groups, strati-
ﬁed by ﬁbrosis stage (S0–S3 and S4–S6), showed similar clinical
and demographic features, except that the S0–S3 group treated
with PegIFNa-2B had a lower HCV RNA value (HCV RNA log10,
IU/ml) than the group treated with PegIFNa-2A (5.79 ± 0.4 vs.
5.93 ± 0.5 IU/ml; p <0.001). In the S0–S3 group, patients treated
with PegIFNa-2B had an ETR of 66.3% compared to 71.7% for those
treated with PegIFNa-2A; the SVRs were 58% vs. 53%, respectively.
In the S4-S6 group, patients treated with PegIFNa-2B had an ETR
of 44.8% compared to 62.5% for those treated with PegIFNa-2A
(p <0.06); the SVRs were 34.4% vs. 40.2%, respectively (not statis-
tically signiﬁcant). By step-logistic regression analysis, signiﬁcant
predictor of treatment failure was a stagingP4, in both the Peg-
IFNa-2B and PegIFNa-2A treatment groups. Moreover, signiﬁcant
predictors of SVR were an RVR in both antiviral treatment groups
andmale sex in the PegIFNa-2B treatment group (Table 1). In con-
clusion, in Italian patients with genotype 1 HCV infection treated
with PegIFNa-2B or PegIFNa-2A plus ribavirin, a stagingP4 inﬂu-
enced the achievement of SVR with both treatments. The Chariot
study demonstrated that, despite adequate therapeutic dosing
with PegIFNa-2A plus ribavirin, there was a low virological
response and a high relapse rate in patients infected with geno-
type 1 that had advanced ﬁbrosis [8]. In fact, a marked step-wise
decline in SVRwas associated with ﬁbrosis stage, evaluated by the
METAVIR score. Advanced liver ﬁbrosis remained the strongest
negative predictive factor of SVR in patients infected with geno-
type 1 and treated with antiviral therapy, despite the use of differ-
ent types of pegylated interferon.
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Table 1. Odds ratio and corresponding 95% conﬁdence intervals (95% CI) from
the multivariate logistic regression analysis including independent predictors
of treatment achievement or failure.
OR 95% CI p value
PegIFNα-2B
Male 3.1 1.0-9.0 0.035
RVR+ 22.1 6.8-31.1 0.001
S ≥4 0.78 0.5-0.9 0.04
PegIFNα-2A
RVR+ 11.4 4.7-27.6 0.001
S ≥4 0.46 0.2-0.8 0.017
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